naxsign.blogg.se - Metoprolol succinate er 25 mg

Abrupt Cessation of Therapy: Following abrupt cessation of therapy with certain beta-blocking agents, exacerbations of angina pectoris and, in some cases, myocardial infarction have occurred.

Kapspargo Sprinkle™ is contraindicated in patients with: IMPORTANT SAFETY INFORMATION Contraindications

Heart failure, to reduce the risk of cardiovascular mortality and hospitalization in patients with heart failure.

Long-term treatment to reduce angina attacks and to improve exercise tolerance Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily stroke and myocardial infarction.

Hypertension, to lower blood pressure.

Kapspargo Sprinkle™ extended-release capsules are beta 1-selective adrenoceptor blocking agent indicated for the treatment of: Please see full Important Safety Information on this page.

Cardiogenic shock or decompensated heart failure.Severe bradycardia, greater than first-degree heart block, or sick sinus syndrome without a pacemaker.Known hypersensitivity to the product components.Kapspargo Sprinkle TM is contraindicated in patients with: View the video below to learn how Kapspargo Sprinkle™ delivers a controlled and predictable release of metoprolol. Designed to deliver metoprolol continuously over the dosage interval 1.Each pellet acts as a separate drug-delivery unit 1.

Contains metoprolol succinate in a multitude of controlled-release pellets 1.Capsules comprise a multiple unit system 1.1 The capsules have been formulated to provide a controlled and predictable release of metoprolol succinate administered once daily. Kapspargo Sprinkle™ is the first and only FDA-approved extended-release sprinkle formulation of metoprolol succinate. Unique formulation A Unique Extended-Release Formulation of Metoprolol Succinate 1